As previously noted, particularly in 2016-E2020, trials initiated for hematologic cancers far exceeded those for solid tumors with most of the hematologic trials (90%) being CAR-Ts targeting either B-cell leukemias and lymphomas (404 out of 529 trials with 368 targeting CD19) or multiple myeloma (99 trials of which 85 target BCMA) (Figure 5A–C). Here, CD19 is linked to plasma cell myeloma.